NASDAQ:MASI - Masimo Stock Price, Forecast & News

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Masimo Co. (NASDAQ:MASI) issued its quarterly earnings results on Wednesday, February, 19th. The medical equipment provider reported $0.91 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.87 by $0.04. The medical equipment provider had revenue of $247.51 million for the quarter, compared to analysts' expectations of $243.79 million. Masimo had a return on equity of 17.03% and a net margin of 20.92%. The firm's revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.83 earnings per share. View Masimo's Earnings History.

Masimo is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Masimo.

Masimo updated its FY20 earnings guidance on Wednesday, February, 19th. The company provided earnings per share (EPS) guidance of $3.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.56. The company issued revenue guidance of $1035 million, compared to the consensus revenue estimate of $1.03 billion.

6 equities research analysts have issued 1 year price targets for Masimo's shares. Their forecasts range from $134.50 to $207.00. On average, they expect Masimo's stock price to reach $181.42 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Price Targets for Masimo.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Masimo.

Media headlines about MASI stock have been trending very positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Masimo earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Masimo.

Masimo saw a decline in short interest in January. As of January 31st, there was short interest totalling 999,000 shares, a decline of 34.7% from the January 15th total of 1,530,000 shares. Based on an average daily volume of 323,800 shares, the short-interest ratio is currently 3.1 days. Currently, 2.0% of the shares of the company are short sold. View Masimo's Current Options Chain.

Some companies that are related to Masimo include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Walt Disney (DIS), Netflix (NFLX), Mastercard (MA), Alibaba Group (BABA), Paypal (PYPL), Shopify (SHOP), Twilio (TWLO), Visa (V) and Trade Desk (TTD).

Masimo's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (8.82%), Citigroup Inc. (2.88%), Massachusetts Financial Services Co. MA (2.49%), State Street Corp (2.23%), Champlain Investment Partners LLC (2.00%) and Bank of New York Mellon Corp (1.86%). Company insiders that own Masimo stock include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee. View Institutional Ownership Trends for Masimo.

MASI stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., AQR Capital Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., First Trust Advisors LP, Renaissance Technologies LLC, Bank of New York Mellon Corp and Janus Henderson Group PLC. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee. View Insider Buying and Selling for Masimo.

MASI stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., FMR LLC, Massachusetts Financial Services Co. MA, Westfield Capital Management Co. LP, Bank of Montreal Can, Champlain Investment Partners LLC, TD Asset Management Inc. and UBS Group AG. View Insider Buying and Selling for Masimo.

Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MASI stock can currently be purchased for approximately $171.44.

Masimo has a market capitalization of $9.14 billion and generates $937.84 million in revenue each year. The medical equipment provider earns $196.22 million in net income (profit) each year or $3.22 on an earnings per share basis. Masimo employs 1,600 workers across the globe.View Additional Information About Masimo.

The official website for Masimo is http://www.masimo.com/.

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]